{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T15:09:27Z","timestamp":1766848167085,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001873"],"award-info":[{"award-number":["UL1TR001873"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00259-022-06027-w","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T08:04:45Z","timestamp":1667981085000},"page":"692-700","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Preliminary efficacy of [90Y]DOTA-biotin-avidin radiotherapy against non-muscle invasive bladder cancer"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7065-6353","authenticated-orcid":false,"given":"Alessandra","family":"Al\u00ec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dev","family":"Leibowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikunj","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail","family":"Doubrovin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine S.","family":"Spina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gleneara E.","family":"Bates-Pappas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert N.","family":"Taub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"McKiernan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiva","family":"Mintz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei","family":"Molotkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"6027_CR1","doi-asserted-by":"publisher","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021. https:\/\/doi.org\/10.3322\/caac.21660","DOI":"10.3322\/caac.21660"},{"key":"6027_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.06.010","author":"S Antoni","year":"2017","unstructured":"Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017. https:\/\/doi.org\/10.1016\/j.eururo.2016.06.010.","journal-title":"Eur Urol"},{"key":"6027_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.07.033","author":"M Burger","year":"2013","unstructured":"Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013. https:\/\/doi.org\/10.1016\/j.eururo.2012.07.033.","journal-title":"Eur Urol"},{"key":"6027_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73370-z","author":"B Somuncu","year":"2020","unstructured":"Somuncu B, Keskin S, Antmen FM, Saglican Y, Ekmekcioglu A, Ertuzun T, et al. Non-muscle invasive bladder cancer tissues have increased base excision repair capacity. Sci Rep. 2020. https:\/\/doi.org\/10.1038\/s41598-020-73370-z.","journal-title":"Sci Rep"},{"key":"6027_CR5","doi-asserted-by":"publisher","unstructured":"Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, B\u00f6hle A, Palou-Redorta J, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011; https:\/\/doi.org\/10.1016\/j.eururo.2011.03.017.","DOI":"10.1016\/j.eururo.2011.03.017"},{"key":"6027_CR6","doi-asserted-by":"publisher","unstructured":"Babjuk M, Burger M, Comp\u00e9rat EM, Gontero P, Mostafid AH, Palou J, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma In Situ) - 2019 update. Eur Urol. 2019. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.016","DOI":"10.1016\/j.eururo.2019.08.016"},{"key":"6027_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.06.049","author":"SS Chang","year":"2016","unstructured":"Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol. 2016. https:\/\/doi.org\/10.1016\/j.juro.2016.06.049.","journal-title":"J Urol"},{"issue":"4","key":"6027_CR8","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","volume":"161","author":"PU Malmstr\u00f6m","year":"1999","unstructured":"Malmstr\u00f6m PU, Wijkstr\u00f6m H, Lundholm C, Wester K, Busch C, Norl\u00e9n BJ. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol. 1999;161(4):1124\u20137.","journal-title":"J Urol"},{"key":"6027_CR9","doi-asserted-by":"publisher","DOI":"10.2174\/18744710113066660023","author":"A Dash","year":"2013","unstructured":"Dash A, Knapp FF, Pillai MR. Targeted radionuclide therapy\u2013an overview. Curr Radiopharm. 2013. https:\/\/doi.org\/10.2174\/18744710113066660023.","journal-title":"Curr Radiopharm"},{"key":"6027_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/BF03164831","author":"CA Hoefnagel","year":"1998","unstructured":"Hoefnagel CA. Radionuclide cancer therapy. Ann Nucl Med. 1998. https:\/\/doi.org\/10.1007\/BF03164831.","journal-title":"Ann Nucl Med"},{"key":"6027_CR11","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.19.2.285","author":"MA Fortin","year":"2007","unstructured":"Fortin MA, Orlova A, Malmstr\u00f6m PU, Tolmachev V. Labelling chemistry and characterization of [90Y\/177Lu]-DOTA-ZHER2:342\u20133 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. Int J Mol Med. 2007. https:\/\/doi.org\/10.3892\/ijmm.19.2.285.","journal-title":"Int J Mol Med"},{"key":"6027_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1988.tb22372.x","author":"R Lotan","year":"1988","unstructured":"Lotan R, Raz A. Lectins in cancer cells. Ann N Y Acad Sci. 1988. https:\/\/doi.org\/10.1111\/j.1749-6632.1988.tb22372.x.","journal-title":"Ann N Y Acad Sci"},{"key":"6027_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1988.tb22373.x","author":"M Monsigny","year":"1988","unstructured":"Monsigny M, Roche AC, Midoux P. Endogenous lectins and drug targeting. Ann N Y Acad Sci. 1988. https:\/\/doi.org\/10.1111\/j.1749-6632.1988.tb22373.x.","journal-title":"Ann N Y Acad Sci"},{"key":"6027_CR14","doi-asserted-by":"publisher","DOI":"10.3109\/10611869509059211","author":"MS Wadhwa","year":"1995","unstructured":"Wadhwa MS, Rice KG. Receptor mediated glycotargeting. J Drug Target. 1995. https:\/\/doi.org\/10.3109\/10611869509059211.","journal-title":"J Drug Target"},{"key":"6027_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwz001","author":"T Vi\u0161njar","year":"2019","unstructured":"Vi\u0161njar T, Romih R, Zupan\u010di\u010d D. Lectins as possible tools for improved urinary bladder cancer management. Glycobiology. 2019. https:\/\/doi.org\/10.1093\/glycob\/cwz001.","journal-title":"Glycobiology"},{"key":"6027_CR16","doi-asserted-by":"publisher","DOI":"10.1021\/bc300030d","author":"M Futami","year":"2012","unstructured":"Futami M, Watanabe Y, Asama T, Murata H, Tada H, Kosaka M, et al. Uniformly cationized protein efficiently reaches the cytosol of mammalian cells. Bioconjug Chem. 2012. https:\/\/doi.org\/10.1021\/bc300030d.","journal-title":"Bioconjug Chem"},{"key":"6027_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(03)00369-5","author":"M Chinol","year":"2003","unstructured":"Chinol M, De Cobelli O, Trifir\u00f2 G, Scardino E, Bartolomei M, Verweij F, et al. Localization of avidin in superficial bladder cancer: a potentially new approach for radionuclide therapy. Eur Urol. 2003. https:\/\/doi.org\/10.1016\/S0302-2838(03)00369-5.","journal-title":"Eur Urol"},{"issue":"3","key":"6027_CR18","first-page":"78","volume":"38","author":"MB St Clair","year":"1999","unstructured":"St Clair MB, Sowers AL, Davis JA, Rhodes LL. Urinary bladder catheterization of female mice and rats. Contemp Top Lab Anim Sci. 1999;38(3):78\u20139.","journal-title":"Contemp Top Lab Anim Sci"},{"key":"6027_CR19","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/61\/6\/2333","author":"T Kostou","year":"2016","unstructured":"Kostou T, Papadimitroulas P, Loudos G, Kagadis GC. A preclinical simulated dataset of S-values and investigation of the impact of rescaled organ masses using the MOBY phantom. Phys Med Biol. 2016. https:\/\/doi.org\/10.1088\/0031-9155\/61\/6\/2333.","journal-title":"Phys Med Biol"},{"key":"6027_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/0300985814522819","author":"DG Sledge","year":"2015","unstructured":"Sledge DG, Patrick DJ, Fitzgerald SD, Xie Y, Kiupel M. Differences in expression of uroplakin III, cytokeratin 7, and cyclooxygenase-2 in canine proliferative urothelial lesions of the urinary bladder. Vet Pathol. 2015. https:\/\/doi.org\/10.1177\/0300985814522819.","journal-title":"Vet Pathol"},{"key":"6027_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.11.128","author":"K Matsumoto","year":"2008","unstructured":"Matsumoto K, Satoh T, Irie A, Ishii J, Kuwao S, Iwamura M, et al. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer. Urology. 2008. https:\/\/doi.org\/10.1016\/j.urology.2007.11.128.","journal-title":"Urology"},{"key":"6027_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2013.07.017","author":"D Gandhi","year":"2013","unstructured":"Gandhi D, Molotkov A, Batourina E, Schneider K, Dan H, Reiley M, et al. Retinoid signaling in progenitors controls specification and regeneration of the urothelium. Dev Cell. 2013. https:\/\/doi.org\/10.1016\/j.devcel.2013.07.017.","journal-title":"Dev Cell"},{"key":"6027_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2003.04655.x","author":"MD Shelley","year":"2004","unstructured":"Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004. https:\/\/doi.org\/10.1111\/j.1464-410X.2003.04655.x.","journal-title":"BJU Int"},{"issue":"5","key":"6027_CR24","first-page":"1697","volume":"162","author":"JA Smith Jr","year":"1999","unstructured":"Smith JA Jr, Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association J Urol. 1999;162(5):1697\u2013701.","journal-title":"The American Urological Association J Urol"},{"key":"6027_CR25","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.49.1.33","author":"DM Parkin","year":"1999","unstructured":"Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999. https:\/\/doi.org\/10.3322\/canjclin.49.1.33.","journal-title":"CA Cancer J Clin"},{"key":"6027_CR26","doi-asserted-by":"publisher","unstructured":"Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007.https:\/\/doi.org\/10.1016\/j.juro.2007.09.003.","DOI":"10.1016\/j.juro.2007.09.003"},{"key":"6027_CR27","doi-asserted-by":"publisher","DOI":"10.2217\/hep.14.6","author":"R Golfieri","year":"2014","unstructured":"Golfieri R. SIR-Spheres yttrium-90 radioembolization for the treatment of unresectable liver cancers. Hepatic Oncol. 2014. https:\/\/doi.org\/10.2217\/hep.14.6.","journal-title":"Hepatic Oncol"},{"key":"6027_CR28","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.065961","author":"P Birgit","year":"2009","unstructured":"Birgit P, Seidl C, Autenrieth M, Saur D, Bruchertseifer F, Morgenstern A, et al. Intravesical \u03b1-radioimmunotherapy with 213 Bi-anti-EGFR-MAb defeats human bladder carcinoma in xenografted nude mice. J Nucl Med. 2009. https:\/\/doi.org\/10.2967\/jnumed.109.065961.","journal-title":"J Nucl Med"},{"key":"6027_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120561","author":"SHL Frost","year":"2015","unstructured":"Frost SHL, Frayo SL, Miller BW, Orozco JJ, Booth GC, Hylarides MD, et al. Comparative efficacy of 177Lu and 90Y for Anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models. PLoS ONE. 2015. https:\/\/doi.org\/10.1371\/journal.pone.0120561.","journal-title":"PLoS ONE"},{"key":"6027_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1413","author":"DE Milenic","year":"2004","unstructured":"Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov. 2004. https:\/\/doi.org\/10.1038\/nrd1413.","journal-title":"Nat Rev Drug Discov"},{"key":"6027_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/srep18905","author":"C Dong","year":"2016","unstructured":"Dong C, Yang S, Shi J, Zhao H, Zhong L, Liu Z, et al. SPECT\/NIRF Dual modality imaging for detection of intraperitoneal colon tumor with an avidin\/biotin pretargeting system. Sci Rep. 2016. https:\/\/doi.org\/10.1038\/srep18905.","journal-title":"Sci Rep"},{"key":"6027_CR32","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0173","author":"R Saito","year":"2015","unstructured":"Saito R, Smith CC, Utsumi T, Bixby LM, Kardos J, Wobker SE, et al. Molecular subtype-specific immunocompetent models of high-grade urothelial carcinoma reveal differential neoantigen expression and response to immunotherapy. Cancer Res. 2015. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0173.","journal-title":"Cancer Res"},{"key":"6027_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.02.090","author":"AN Viswanathan","year":"2010","unstructured":"Viswanathan AN, Yorke ED, Marks LB, Eifel PJ, Shipley WU. Radiation dose\u2013volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys. 2010. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.02.090.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-06027-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-06027-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-06027-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T06:08:35Z","timestamp":1674108515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-06027-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["6027"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-06027-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"type":"print","value":"1619-7070"},{"type":"electronic","value":"1619-7089"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"assertion":[{"value":"14 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Institutional Animal Care and Use Committee of Columbia University Irving Medical Center (AC-AABL2550).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RNT and GEB have listed inventors on the patents related to [<sup>90<\/sup>Y]GBA held by Columbia University. RNT and GEB are founders of Biobina, LLC, which is developing [<sup>90<\/sup>Y]GBA as a therapeutic for bladder cancer.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}